🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "significant breakthrough" in the fight against drug-resistant strains of the infection, according to scientists.

A Global Health Concern

The sexually transmitted infection are escalating worldwide, with estimates suggesting over 82 million infections annually. Notably increased rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have reached a historical peak, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary development in the face of rising global incidence, increasing antimicrobial resistance and the extremely scarce available drugs presently on offer.”

Health officials are deeply concerned about the rise in treatment-resistant strains. The WHO has listed it as a "high-priority threat". Ongoing monitoring showed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Receive Approval

One new antibiotic, marketed under the name a brand name, was approved by the US Food and Drug Administration in mid-December for treating gonorrhoea. This disease can lead to major issues, including infertility. Experts believe that targeted use of this new drug will help delay the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GSK, also received approval in concurrent days. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP worked alongside the pharmaceutical company its industry partner to develop it.

“This approval represents a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Outcomes and Worldwide Availability

As per findings published in a prominent scientific publication, zoliflodacin cured the vast majority of cases of the STI. This establishes an similar efficacy with the existing first-line therapy, which uses a dual-drug approach. The study included hundreds of patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the ability to make available and distribute the drug in a wide range of regions with limited resources.

Clinicians directly involved have shared positive views. Access to a one-pill regimen such as this is seen as a "critical tool" for gonorrhoea control. This is deemed crucial to lessen the impact of the infection for patients and to prevent the spread of extremely resistant gonorrhoea around the world.